Treatment of Relapsed or Refractory Diffuse Large B Cell Lymphoma With Ociperlimab (BGB-A1217) in Combination With Tislelizumab (BGB-A317) or Rituximab

Clinical trial NCT05267054 · COMPLETED

Trial details

NCT number: NCT05267054
Sponsor: BeiGene
Status: COMPLETED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Relapsed Diffuse Large B-cell Lymphoma Refractory Diffuse Large B-cell Lymphoma

Start date: 2022-04-25
Primary completion: 2024-08-30
Enrollment: 53

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.